# Halozyme Therapeutics, Inc. (HALO)

> Source: Nexqual · https://nexqual.com/HALO · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Halozyme Therapeutics, Inc. (HALO), nexqual.com/HALO" · informational, not investment advice.

**Price:** USD 124.54 (-0.23% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 124.83 · day 121.66–124.72 · 52w 61.23–125.43 · market cap $14.1B · NMS

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $1.66B, net income $414M (24.9% margin), free cash flow $806M (SEC filings).
- Valuation: P/E 34.2x (avg 19.3x at the last 3 fiscal year-ends), EV/EBITDA 26.2x, net debt $1.92B.
- 2 of 80 tracked superinvestors hold HALO (13F, Q2 2026): 0 new, 1 added, 0 reduced, 1 unchanged.
- Analysts: Buy (mean 2.00 on a 1–5 scale) (9 analysts), mean target USD 108.78 (range 78–130).
- Total return with dividends: 1Y +86.2% vs S&P 500 +14.9%; 5Y +220.4% vs S&P 500 +80.3%.
- Next earnings: 2026-11-05, EPS estimate USD 2.35, revenue estimate $491M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $443M | $660M | $829M | $1.02B | $1.40B | $1.66B |
| Gross profit | $362M | $521M | $637M | $856M | $1.17B | — |
| Operating income | $276M | $268M | $338M | $551M | $469M | $597M |
| Net income | $403M | $202M | $282M | $444M | $317M | $414M |
| EPS (diluted) | $2.74 | $1.44 | $2.10 | $3.43 | $2.56 | — |
| Free cash flow | $298M | $235M | $373M | $468M | $645M | $806M |
| Gross margin | 81.6% | 78.9% | 76.8% | 84.3% | 83.6% | — |
| Operating margin | 62.2% | 40.5% | 40.7% | 54.3% | 33.6% | 35.9% |
| Net margin | 90.8% | 30.6% | 34.0% | 43.7% | 22.7% | 24.9% |
| Revenue growth | +65.7% | +48.9% | +25.6% | +22.4% | +37.6% | — |
| Cash + short-term investments | $741M | $363M | $336M | $596M | $143M | — |
| Total debt | $877M | $1.51B | $1.50B | $1.51B | $2.14B | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/E 34.2x · P/S 8.5x · EV/EBITDA 26.2x · EV/Sales 9.7x · P/FCF 17.5x · P/B 98.5x · FCF yield 5.70% · Earnings yield 2.93% · Net debt $1.92B · EV $16.1B
P/E at fiscal year-ends: Dec 2025 26.3x, Dec 2024 13.9x, Dec 2023 17.6x.

## Superinvestors (SEC 13F-HR, Q2 2026)
2 of 80 tracked investors hold HALO. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Torray Funds |  | 0.41% | $3.0M | Added +1.4% |
| Richard Pzena | Pzena Investment Management | <0.01% | $317K | Unchanged |

## Analysts
Consensus Buy (mean 2.00 on a 1–5 scale), 9 analysts; mean target USD 108.78 (low 78, high 130).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-13 | TD Cowen | Target raised | Buy | $105 → $130 |
| 2026-10-08 | JP Morgan | Target raised | Neutral | $70 → $78 |
| 2026-10-08 | HC Wainwright & Co. | Target raised | Buy | $115 → $130 |
| 2026-09-02 | HC Wainwright & Co. | Reiterated | Buy | $115 |
| 2026-08-08 | Leerink Partners | Upgrade | Market Perform → Outperform | $83 → $110 |
| 2026-08-07 | TD Cowen | Target raised | Buy | $96 → $105 |
| 2026-08-07 | Citizens | Target raised | Market Outperform | $92 → $93 |
| 2026-08-07 | Wells Fargo | Target raised | Equal-Weight | $75 → $95 |
| 2026-08-07 | HC Wainwright & Co. | Target raised | Buy | $95 → $115 |
| 2026-07-21 | HC Wainwright & Co. | Reiterated | Buy | $95 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | +86.2% | +220.4% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +86.6% | +26.1% |
| Volatility (annualized) | 36.5% | 42.0% |
| Max drawdown | -24.1% (Feb 2026→Mar 2026) | -47.9% (Nov 2022→May 2023) |

## Peers (Biotechnology)
JAZZ (Jazz Pharmaceuticals plc) USD 214.65 +1.26% · BBIO (BridgeBio Pharma, Inc.) USD 68.12 +0.56% · ASND (Ascendis Pharma A/S) USD 242.99 +1.71% · SMMT (Summit Therapeutics Inc.) USD 15.55 -1.77% · CORT (Corcept Therapeutics Incorporat) USD 107.5 -7.55% · EXEL (Exelixis, Inc.) USD 65.31 +1.13%

## More
Full page: https://nexqual.com/HALO · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)


Other companies that name HALO in their own reports (relationship from HALO's side):

| Relationship | Company | Their filing | Sentence |
|---|---|---|---|
| partner | ARGENX SE (ARGX) | 20-F 2026-03-19 | "In February 2019, the Company entered into a global collaboration and license agreement with Halozyme Therapeutics," |

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $2.35 | $2.19 | +7.3% | $490.8M | 6 |
| Next quarter (ends 2026-12-31) | $2.62 | $2.55 | +2.8% | $537.6M | 6 |
| Current fiscal year (ends 2026-12-31) | $8.84 | $8.12 | +8.8% | $1.88B | 6 |
| Next fiscal year (ends 2027-12-31) | $10.68 | $9.91 | +7.7% | $2.10B | 5 |